Compare Ascendis Pharma A/S (ASND) vs Direxion Daily Semiconductor Bear 3X Shares (SOXS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Ascendis Pharma A/S trades at $260.65 (market cap $16.67B), while Direxion Daily Semiconductor Bear 3X Shares trades at $40.72. Which is the better fit depends on your goals.
| ASND | SOXS | |
|---|---|---|
Market Cap | $16.67B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $277.18 | $1.49K |
52-Week Low | $189.74 | $32.50 |
Enterprise Value | $17.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.
ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, is trading at $40.97, down 9.38% today amid volatile semiconductor sector conditions. The technical picture remains bearish with moving averages signaling continued downward pressure, though oversold RSI levels suggest potential for near-term bounce. Recent news highlights SOXS benefiting from AI-fueled tech rally concerns and semiconductor stock sell-offs, with the fund executing a 1:10 stock split effective July 26, 2026.
As a leveraged inverse ETF, SOXS offers amplified exposure to semiconductor sector declines but carries significant decay and volatility risks. The fund's performance is heavily dependent on continued semiconductor weakness, which faces fundamental challenges from AI infrastructure growth and memory chip competition. Investors should understand the complex nature of inverse leveraged products before considering positions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →
